It is going up, 3000 plus physicians now prescribing Qsymia, 60 million obese in the US alone. 80 to 90 % of trial participants happy with results and stayed on Qsymia for the length of the clinical trial. Q4 results to confirm.
Let's put all the bashing and insults aside and just look at the numbers based on Vivus last conference call. They have a very expensive REMS process to fund without a partner. This will burn their cash very quickly. Until they show the finacial community clarity on how Qsymia will generate the revenue required, or they announce a partner (nothing on the horizon there), this will be a very risky investment. Expect a secondary next quarter if they can even pull one off.